169 related articles for article (PubMed ID: 31869407)
1. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
De Stefano V; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
Blood; 2020 Jan; 135(5):381-386. PubMed ID: 31869407
[TBL] [Abstract][Full Text] [Related]
2. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G
Leukemia; 2019 Aug; 33(8):1996-2005. PubMed ID: 31142846
[TBL] [Abstract][Full Text] [Related]
3. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Krashin E; Cohen O; Pereg D; Lishner M; Leader A
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
5. [The Risk Factors of Thrombosis in Patients with Philadelphia Chromosome-negative Myeloproliferative Neoplasms].
Zhao YF; Lin SZ; Bai X; Xing XY; Tao HF; Su YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1869-1874. PubMed ID: 34893125
[TBL] [Abstract][Full Text] [Related]
6. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
7. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Hasselbalch HC; Elvers M; Schafer AI
Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and management of children, adolescents, and young adults with Philadelphia chromosome-negative myeloproliferative neoplasms].
Sugimoto Y
Rinsho Ketsueki; 2023; 64(10):1314-1325. PubMed ID: 37914247
[TBL] [Abstract][Full Text] [Related]
9. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
[TBL] [Abstract][Full Text] [Related]
11. Second cancers in MPN: Survival analysis from an international study.
Marchetti M; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Pane F; De Stefano V; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
Am J Hematol; 2020 Mar; 95(3):295-301. PubMed ID: 31816122
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
[TBL] [Abstract][Full Text] [Related]
14. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
15. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
16. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
17. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
18. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
19. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
